BioXcel Therapeutics, Inc. (BTAI)New Haven, United States |
USD
|
Hot Take ↕ | Oct. 10, 2026, 7:54 a.m. UTC
The immediate outlook is severely clouded by a brutal recent price collapse, where the stock traded in the $0.04 to $0.06 range for nearly two weeks, signaling intense selling pressure and a lack of near-term support. This technical breakdown, combined with a forward P/E of negative infinity due to losses, suggests a high-risk environment unsuitable for capital preservation. Looking further ahead, the fundamental picture is dire: the company is burning through cash at an alarming rate with operating cash flow of -$50.9 million and free cash flow of -$31.7 million, while carrying debt of $104.5 million against only $12.8 million in cash. The balance sheet is fragile with a current ratio of just 0.21, indicating severe liquidity stress. Although revenue growth of 51.7% offers a glimmer of operational traction, it cannot offset the massive cash bleed or the deteriorating operating margins of -56%. With no dividend history and a market cap of merely $2.3 million, there is no safety net. The stock appears to be in a survival mode rather than a growth phase, making it a poor candidate for both short-term trades and long-term holding. |
| Attribute | Value |
|---|---|
| Revenue per Share | 0.033 |
| Market Cap | 2,313,476 |
| Forward P/E | -0.03 |
| Beta | 0.19 |
| Website | https://www.bioxceltherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7060811 |
| Address1 | 555 Long Wharf Drive |
| Address2 | 12th Floor |
| All Time High | 0.197 |
| All Time Low | 0.019 |
| Ask | 0.1227 |
| Ask Size | 100 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 367,245 |
| Average Volume | 11,060,266 |
| Average Volume10Days | 367,245 |
| Beta | 0.188 |
| Bid | 0.16 |
| Bid Size | 100 |
| Board Risk | 7 |
| Book Value | -3.688 |
| City | New Haven |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Currency | USD |
| Current Price | 0.0739 |
| Current Ratio | 0.209 |
| Day High | 0.0935 |
| Day Low | 0.069 |
| Ebitda | -44,507,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.095 |
| Enterprise To Revenue | 125.658 |
| Enterprise Value | 93,237,888 |
| Exchange | NCM |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 0.063072845 |
| Fifty Two Week High | 0.197 |
| Fifty Two Week Low | 0.019 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,295,000 |
| Float Shares | 26,891,737 |
| Forward Eps | -2.14 |
| Forward P E | -0.034532707 |
| Free Cashflow | -31,745,500 |
| Full Time Employees | 29 |
| Fullday Change | 0.0739 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 0.0739 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.53099996 |
| Gross Profits | 394,000 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.102790006 |
| Implied Shares Outstanding | 31,305,499 |
| Industry | |
| Industry Key | |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. On August 27, 2026, BioXcel Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. |
| Long Name | BioXcel Therapeutics, Inc. |
| Market Cap | 2,313,476 |
| Max Age | 86,400 |
| Message Board Id | finmb_543567629 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -70,860,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,408,747 |
| Open | 0.091 |
| Operating Cashflow | -50,904,000 |
| Operating Margins | -56.00549 |
| Overall Risk | 6 |
| Phone | 475 238 6837 |
| Previous Close | 0.0 |
| Price Hint | 4 |
| Price To Sales Trailing12 Months | 3.1178923 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.094 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Regular Market Day High | 0.0935 |
| Regular Market Day Low | 0.069 |
| Regular Market Open | 0.091 |
| Regular Market Previous Close | 0.0 |
| Regular Market Volume | 47,480,718 |
| Return On Assets | -1.02431 |
| Revenue Growth | 0.517 |
| Revenue Per Share | 0.033 |
| Sand P52 Week Change | 0.17004645 |
| Sector | |
| Sector Key | |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 31,305,499 |
| Short Name | BioXcel Therapeutics, Inc. |
| State | CT |
| Symbol | BTAI |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 12,841,000 |
| Total Cash Per Share | 0.41 |
| Total Debt | 104,451,000 |
| Total Revenue | 742,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | -2.58 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 0.063072845 |
| Underlying Symbol | BTAI |
| Uuid | ed3396e0-a498-379a-b23a-cf6795d0f871 |
| Volume | 47,480,718 |
| Website | https://www.bioxceltherapeutics.com |
| Zip | 6,511 |